AMPH
Amphastar Pharmaceuticals, Inc.
-0.25 (-1.04%)23.70USD95.6K成交股數1.0B市值14.0本益比(近四季)1.4股價營收比+5.4%營收年增(近四季)2026-11-05下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 12 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | 184M+5% | 171M+0% | 183M-4% | 192M+5% | 174M+2% | 171M-4% | 191M+6% | 182M+25% | 172M | 178M | 181M | 146M |
| 營業成本 | 90.4M | 101M | 97.4M | 93.2M | 87.9M | 85.3M | 89.3M | 87.2M | 81.7M | 82.0M | 72.2M | 73.0M |
| 毛利 | 93.5M+8% | 70.3M-18% | 85.7M-16% | 98.6M+4% | 86.5M-4% | 85.3M-11% | 102M-6% | 95.2M+31% | 90.1M | 96.1M | 108M | 72.7M |
| 毛利率 | 50.8% | 41.1% | 46.8% | 51.4% | 49.6% | 50.0% | 53.3% | 52.2% | 52.4% | 54.0% | 60.0% | 49.9% |
| 研發費用 | 22.2M | 26.7M | 23.3M | 22.4M | 20.1M | 20.1M | 21.1M | 17.7M | 17.0M | 20.4M | 16.7M | 16.8M |
| 銷售管理費用 | 18.2M | 18.0M | 16.5M | 39.5M | 14.0M | 16.0M | 14.8M | 13.3M | 15.7M | 13.1M | 12.7M | 12.3M |
| 營業利益 | 39.7M-6% | 13.6M-63% | 35.6M-38% | 25.3M-54% | 42.2M-12% | 37.3M-31% | 57.0M-22% | 55.2M+50% | 48.0M | 54.0M | 72.7M | 36.9M |
| 營業利益率 | 21.6% | 8.0% | 19.4% | 13.2% | 24.2% | 21.9% | 29.8% | 30.3% | 27.9% | 30.3% | 40.3% | 25.3% |
| 稅後淨利 | 30.3M-2% | 6.4M-75% | 24.4M-40% | 17.4M-54% | 31.0M-28% | 25.3M-30% | 40.4M-18% | 37.9M+45% | 43.2M | 36.2M | 49.2M | 26.1M |
| 淨利率 | 16.5% | 3.8% | 13.3% | 9.0% | 17.8% | 14.8% | 21.1% | 20.8% | 25.1% | 20.3% | 27.3% | 17.9% |
| 稀釋 EPS | 0.67+5% | 0.14-73% | 0.51-35% | 0.37-49% | 0.64-21% | 0.51-27% | 0.78-14% | 0.73+49% | 0.81 | 0.70 | 0.91 | 0.49 |
| 稀釋股數 | 44.2M | 46.5M | 48.2M | 47.7M | 48.1M | 49.9M | 51.9M | 52.0M | 53.0M | 53.0M | 53.9M | 53.1M |
資產負債表 期末餘額
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 224M | 171M | 170M | 216M | 188M | 183M | 192M | 190M | 201M | 144M | 267M | 149M |
| 應收帳款 | 145M | 148M | 144M | 147M | 133M | 145M | 140M | 131M | 138M | 115M | 119M | 105M |
| 存貨 | 180M | 170M | 177M | 186M | 192M | 185M | 130M | 122M | 115M | 106M | 110M | 105M |
| 總資產 | 1.7B | 1.6B | 1.6B | 1.7B | 1.6B | 1.6B | 1.5B | 1.5B | 1.6B | 1.5B | 1.5B | 1.4B |
| 有息負債 | 610M | 610M | 620M | 609M | 608M | 604M | 596M | 587M | 594M | 603M | 653M | 488M |
| 總負債 | 976M | 875M | 840M | 889M | 858M | 875M | 818M | 778M | 902M | 873M | 949M | 789M |
| 股東權益 | 768M | 773M | 789M | 777M | 757M | 751M | 728M | 713M | 672M | 639M | 595M | 589M |
| 負債比 | 55.9% | 53.1% | 51.6% | 53.4% | 53.1% | 53.8% | 52.9% | 52.2% | 57.3% | 57.7% | 61.5% | 57.2% |
| 淨現金(現金 − 有息負債) | −386M | −439M | −450M | −392M | −420M | −421M | −404M | −397M | −393M | −459M | −386M | −340M |
現金流量表 單季
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | – | 47.8M+36% | – | – | – | 35.1M | – | – | 55.3M | – | – | – |
| 資本支出 | – | 9.5M | – | – | – | 10.7M | – | – | 8.8M | – | – | – |
| 自由現金流 | – | 38.3M+57% | – | – | – | 24.4M | – | – | 46.5M | – | – | – |
| 折舊攤銷 | 14.3M | – | – | 14.1M | 14.6M | – | 13.4M | 13.1M | 9.7M | 9.7M | 9.6M | 3.1M |
| 買回庫藏股 | – | 29.5M | – | – | – | 11.0M | – | – | – | – | – | – |
| 現金股利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流率 | – | 22.4% | – | – | – | 14.3% | – | – | 27.1% | – | – | – |
營收拆解 2025 年度 10-K 的分部揭露 · 年增對前一年度
業務分部2025 年度 · 720M
| Pharmaceutical Products | 720M | 100.0% | -1.7% |
|---|
地區2025 年度 · 720M
| 美國 | 681M | 94.7% | -3.7% |
|---|---|---|---|
| 法國 | 35.3M | 4.9% | +76.9% |
| 中國 | 3.2M | 0.4% | -26.6% |
產品／服務2025 年度 · 720M
| 產品 | 720M | 100.0% | +1.0% |
|---|
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2025 | 720M | -1.7% | 98.1M | 13.6% | 2.03 | 121M |
| FY2024 | 732M | +13.6% | 160M | 21.8% | 3.06 | 172M |
| FY2023 | 644M | +29.1% | 138M | 21.3% | 2.60 | 145M |
| FY2022 | 499M | +14.0% | 91.4M | 18.3% | 1.74 | 65.1M |
| FY2021 | 438M | +25.1% | 62.1M | 14.2% | 1.25 | 70.5M |
| FY2020 | 350M | +8.5% | 1.4M | 0.4% | 0.03 | 23.4M |
| FY2019 | 322M | +9.4% | 48.9M | 15.2% | 0.98 | 207K |
| FY2018 | 295M | – | −5.7M | -1.9% | -0.12 | −8.6M |